Wilson's Disease — Comprehensive Clinical Overview

Bilateral Kayser-Fleischer rings — pathognomonic sign of Wilson disease

1. Definition

• Goldman-Cecil Medicine, p. 2325 | Harrison's Principles of Internal Medicine 22E, p. 3382

2. Epidemiology

• Goldman-Cecil Medicine, p. 2325 | Harrison's, p. 3383

3. Etiology

• 650 pathogenic or likely pathogenic variants are catalogued in major ATP7B databases

• Most patients are compound heterozygotes (different mutations on each allele)
• Common variants include H1069Q (common in Europeans), M645R, and R778L (common in East Asians)
• Large deletions are relatively uncommon; most pathogenic variants (~97%) are in coding exons or intronic sequences
• Related gene ATP7A (mutated in Menkes disease) is X-linked; ATP7B is autosomal
• Modifier genes (e.g., CAT, SOD2, MTHFR) may influence clinical expression in some individuals
• Harrison's, p. 3383 | Goldman-Cecil, p. 2325

4. Risk Factors

• Family history: First-degree relatives of an index case have a 1 in 4 risk (autosomal recessive); siblings must be screened
• Consanguinity: Increases risk of homozygous mutations
• Dietary copper excess: High-copper foods (shellfish, liver, nuts, chocolate, mushrooms) can precipitate or accelerate manifestations in affected individuals
• Drinking water copper: Concentrations approaching 1.3 mg/L from copper pipes can worsen copper loading
• Non-compliance with treatment: Leads to symptomatic relapse and liver failure even in previously well-controlled patients

5. Pathophysiology

Copper metabolism and consequences of ATP7B mutation — Robbins Basic Pathology

• 1–3 mg dietary copper consumed daily; ~50% absorbed in stomach and duodenum via hCTR1 transporter
• Copper carried by albumin/amino acids to the liver via portal blood
• In hepatocytes, copper is: (1) incorporated into ceruloplasmin via ATP7B in the trans-Golgi network; (2) used in copper-dependent enzymes; (3) stored bound to metallothionein; or (4) excreted into bile via ATP7B in lysosomes
• Biliary excretion is the major route of copper elimination — bile copper does not undergo enterohepatic recirculation

1. Biliary copper excretion fails → hepatic copper accumulates
2. Copper accumulates in hepatocyte cytoplasm and lysosomes → increased ROS production → hepatocyte injury (steatosis → acute hepatitis → chronic hepatitis → cirrhosis)
3. With progressive liver damage, non-ceruloplasmin-bound copper is released into circulation → hemolytic anemia, and copper deposition in:
   • Brain (basal ganglia — caudate, putamen; also midbrain, pons, thalamus, cerebellum) → neuropsychiatric disease
   • Cornea (Descemet membrane) → Kayser-Fleischer rings
   • Kidney (proximal tubules) → Fanconi syndrome
   • Bones, joints, parathyroid glands
4. Although serum ceruloplasmin is low (impaired copper loading of apoceruloplasmin → unstable apoprotein), low ceruloplasmin plays no role in the pathogenesis of disease; copper itself drives toxicity

• Robbins Basic Pathology, p. [block 6] | Goldman-Cecil, p. 2325–2326

6. Complications

Hepatic

• Steatosis (fatty liver) — earliest change
• Acute hepatitis (can mimic viral hepatitis)
• Chronic active hepatitis with fibrosis
• Cirrhosis — present in most patients with neurological disease
• Acute liver failure (ALF) — 5% of patients; presents with Coombs-negative hemolytic anemia, coagulopathy, markedly elevated bilirubin; alkaline phosphatase:bilirubin ratio <4 and AST:ALT ratio >2.2 are diagnostic clues

Neurological

• Dysarthria, dystonia, rigidity
• Tremor ("wing-beating" or postural/resting)
• Choreiform movements, ataxia, gait disturbance
• Dysphagia, drooling, "sardonic" smile (risus sardonicus)
• Seizures (minority of patients)
• MRI: abnormal T2/FLAIR signal in putamen, midbrain, pons, thalamus, cerebellum; cerebral atrophy

Psychiatric

• Personality and mood changes (most common — ~50% of patients)
• Depression (~30%)
• Bipolar spectrum symptoms (~20%)
• Suicidal ideation (5–15%)
• Psychosis, anxiety, irritability, aggression
• Cognitive decline (frontosubcortical pattern)

Ophthalmic

• Kayser-Fleischer rings: golden-brown deposits of copper in Descemet membrane at corneal limbus — present in ~95% of patients with neurological disease; ~50–65% with hepatic-only presentation; slit-lamp required for early detection
• Sunflower cataracts: copper in the lens (rare)

Hematological

• Coombs-negative hemolytic anemia: direct toxicity of copper on RBC membranes; can be catastrophic in ALF

Renal

• Renal tubular Fanconi syndrome: aminoaciduria, glycosuria (normoglycemic), phosphaturia, uricosuria, calciuria
• Nephrolithiasis, hypercalciuria

Skeletal

• Osteoporosis, osteomalacia, rickets (from renal calcium/phosphorus loss)
• Osteoarthritis (knees and wrists — from copper in bone/cartilage)

Reproductive

• Secondary amenorrhea, delayed puberty (from liver disease)
• Increased spontaneous miscarriage in untreated pregnant women

7. Diagnosis

Leipzig Scoring System (points)

Key Investigations

• Harrison's, p. 3382–3383 | Goldman-Cecil, p. 2326 | Bradley and Daroff's Neurology

Leipzig scoring diagnostic algorithm for neurological Wilson disease presentation

8. Non-Pharmacological Therapy

Dietary Copper Restriction

• Avoid high-copper foods: shellfish (especially oysters, crab), liver and organ meats, mushrooms, chocolate, nuts, seeds, dried fruit
• Test drinking water: avoid if copper concentration approaches 1.3 mg/L (common from copper plumbing)
• Dietary restriction alone is insufficient but is an important adjunct

Rehabilitation Therapy

• Speech therapy: for dysarthria and dysphagia
• Physical therapy: for tremor, dystonia, gait disturbance, and motor rehabilitation
• Occupational therapy: for handwriting difficulties and activities of daily living
• These are particularly important in newly diagnosed patients with neurological manifestations

Psychological Support

• Neuropsychiatric symptoms are present in up to 70% of patients long-term; psychological evaluation and counseling are integral to management
• Management of depression, anxiety, personality disorders — with specific caution regarding neuroleptic sensitivity

Family Screening and Genetic Counseling

• All first-degree relatives of a diagnosed patient must be screened (serum ceruloplasmin, slit-lamp, urine copper, genetic testing)
• Presymptomatic treatment of affected relatives prevents disease manifestation

Liver Transplantation (Non-pharmacological surgical)

• Indications: ALF unresponsive to medical therapy; end-stage irreversible liver disease; rarely, severe intractable neurological disease
• Outcome: Cures Wilson disease — corrects the metabolic defect, Kayser-Fleischer rings fade, neurological function often improves; disease does not recur
• 5% of patients with ALF require urgent transplantation for survival

9. Pharmacological Therapy

Copper Chelators (First-line for symptomatic patients)

D-Penicillamine (Cuprimine)

• Mechanism: Free thiol binds free copper → dramatically increases urinary copper excretion; does not correct the basic biliary excretion defect
• Dose: Start at 250 mg twice daily; titrate to 15–20 mg/kg/day in 2–4 divided doses
• Pyridoxine (vitamin B6) co-administration: Mandatory to prevent B6 deficiency during chronic use
• Side effects (~20% intolerance):
  • Early: hypersensitivity reactions (rash, fever, lymphadenopathy)
  • Late: nephrotoxicity (membranous glomerulonephritis), hematologic toxicity (thrombocytopenia, leukopenia)
  • Dermatologic: elastosis perforans serpiginosa (distinctive serpiginous rash at neck/axillae)
  • Neurological worsening: 20–50% of neurologically presenting patients experience paradoxical deterioration, some permanent — a major clinical concern
• Monitoring: 24-h urine copper, CBC, urinalysis

Trientine (Triethylenetetramine dihydrochloride — Syprine)

• Mechanism: Chelates copper → enhances urinary copper excretion
• Indication: First-line alternative in patients intolerant of penicillamine; preferred in neurologically presenting patients (lower risk of neurological worsening); noninferior to D-penicillamine for copper maintenance therapy
• Advantages: Better side-effect profile than penicillamine
• Trientine tetrahydrochloride (newer formulation) — demonstrated non-inferiority to D-penicillamine in stable Wilson disease

Tetrathiomolybdate (TM) / Tetrahydroxytetramolybdate (bis-choline tetrathiomolybdate)

• Mechanism: Forms stable tripartite complexes with albumin and copper → reduces both GI copper absorption and circulating free copper; promotes biliary copper excretion
• Advantages: Fast-acting — restores normal copper balance within weeks (vs. months for other agents); may be especially appropriate as initial therapy in neurologically presenting patients due to lower risk of neurological worsening
• Status: Experimental/emerging; phase III trials ongoing

Zinc Salts (Maintenance / Presymptomatic)

Zinc Acetate (Galzin) / Zinc Gluconate / Zinc Sulfate

• Mechanism: Induces metallothionein synthesis in intestinal epithelial cells → metallothionein binds dietary copper in enterocytes → blocked absorption → copper excreted with sloughed enterocytes in feces (does not enhance urinary excretion)
• Indications:
  1. Presymptomatic patients (first-line)
  2. Maintenance therapy after initial "de-coppering" with chelators
  3. Pregnancy (preferred due to safety profile; teratogenic risk of chelators)
• Dose: 150 mg elemental zinc/day in 3 divided doses (taken between meals)
• Advantages: Minimal systemic toxicity; safe in pregnancy
• Disadvantages:
  • Slow onset — 4–6 months to restore copper balance when used as initial monotherapy
  • 10–20% experience dyspepsia
  • Higher incidence of hepatic decompensation with long-term use vs. chelation therapy
  • Not recommended as sole initial therapy in symptomatic patients due to slow action

Treatment in Special Situations

Emerging Therapies

• Gene therapy: Adeno-associated virus (AAV)-mediated ATP7B introduction into hepatocytes — Phase I/II clinical trials ongoing; transduction of only 20% of hepatocytes normalized copper homeostasis in animal models
• Methanobactin: Bacterial peptide with high copper affinity, traverses mitochondrial membranes — preclinical evidence in rat model of advanced Wilson disease

Monitoring of Treatment

• 24-h urine copper: should remain 200–500 μg/day (not zero — over-chelation harmful)
• Serum ceruloplasmin and copper (non-ceruloplasmin-bound "free" copper)
• Liver function tests and CBC (for penicillamine toxicity)
• Slit-lamp exam: Kayser-Fleischer rings fade with effective treatment
• MRI brain: may show partial improvement with sustained treatment

Summary Table

• Goldman-Cecil Medicine International Edition, Chapter 195 (Wilson Disease)
• Harrison's Principles of Internal Medicine 22E (2025), Chapter 427 (Wilson's Disease)
• Robbins & Kumar Basic Pathology, Chapter 14 (Wilson Disease)
• Bradley and Daroff's Neurology in Clinical Practice, Chapter on Wilson Disease
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Chapter on Wilson Disease